Entities / Entity
onasemnogene abeparvovec.
gene therapy product
- Reports this week
- 0
- Active events
- 0
- Connections
- 6
What's happening
No events on record for onasemnogene abeparvovec yet.
No events began in the chosen period. Widen it, or reset.
Around onasemnogene abeparvovec this week
News at the entities that move onasemnogene abeparvovec most-
Novartis StructuralSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves onasemnogene abeparvovec
-
European Commission StructuralThe European Commission signed association agreements with San Marino and Andorra in a ceremony held in Brussels.Moves onasemnogene abeparvovec
-
SMA StructuralFinancial analysis shows minimal ECL impact and low slippages for Karur Vysya Bank, comparing valuation metrics to ABV.Moves onasemnogene abeparvovec
Connections
The 3 strongest of 6, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Structural
Novartis is the company that develops, licenses, and brings the onasemnogene abeparvovec gene therapy product to market.
-
SMA Structural
Company SMA develops and offers the product onasemnogene abeparvovec as a treatment for SMA.
-
European Commission Structural
The European Commission granted regulatory approval for the product onasemnogene abeparvovec.